Combination research — study-design reference
Metabolic peptide combination research
Methodological study-design references for combining metabolic peptides in authorised research. Each page describes mechanism rationale, the published literature supporting the combination concept, and the design considerations for clean experimentation. None of these pages provide protocols for human use, dosing recommendations, or supplier links.
GLP-1 / dual-agonist combination research — study-design reference
Methodological reference for designing GLP-1 / dual-agonist combination research: compound selection (mono- vs dual-agonist), titration logic anchored to published trial schedules, biomarker panels and outcome instrumentation. URL retained for SEO continuity.
Growth-hormone-axis combination research — study-design reference
Methodological reference for designing combination research models on the growth-hormone axis: GHRH analogues (tesamorelin, CJC-1295), GHS-R1a selective agonists (ipamorelin), and lipolytic peptide fragments. Framing is study-design literacy, not human-use protocol. URL retained for SEO continuity.
- They do not endorse, recommend, or instruct any combined human use of the medicines or research compounds discussed.
- They do not provide dosing schedules, titration protocols, or self-administration guidance.
- They do not list, rank or recommend suppliers.
- They are methodological references for authorised research only.